Trials / Terminated
TerminatedNCT02299635
A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
PHASE 2 STUDY OF SINGLE-AGENT PF-03084014 IN PATIENTS WITH ADVANCED TRIPLE-NEGATIVE BREAST CANCER WITH OR WITHOUT GENOMIC ALTERATIONS IN NOTCH RECEPTORS
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the preliminary anti-tumor activity and tolerability of PF-03084014 when administered as a single agent in the treatment of patients with advanced triple receptor-negative breast cancer (mTNBC) harboring genomic alterations in Notch receptors (NA+), and in a smaller subset of mTNBC patients whose tumor tests negative for genomic alterations in Notch receptors (NA-)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-03084014 | Tablet, 10 mg, twice a day. |
| DRUG | PF-03084014 | Tablet, 50 mg, twice a day |
| DRUG | PF-03084014 | Tablet, 100 mg, twice a day |
Timeline
- Start date
- 2015-02-03
- Primary completion
- 2016-01-14
- Completion
- 2016-01-14
- First posted
- 2014-11-24
- Last updated
- 2019-01-08
- Results posted
- 2017-01-13
Locations
37 sites across 6 countries: United States, Hungary, Italy, Poland, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02299635. Inclusion in this directory is not an endorsement.